ClinicalTrials.gg
CompletedNCT02540993FIDELIO-DKDUpdated Jul 24, 2023Results posted

Efficacy and Safety of Finerenone in Subjects With Type 2 Diabetes Mellitus and Diabetic Kidney Disease

A Phase 3 interventional study of Finerenone (BAY94-8862) and Placebo in Chronic Kidney Disease, sponsored by Bayer. Completed at 978 sites in 48 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-07-24.

Sponsored by Bayer · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
5,734
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 25 studies testing finerenone in Renal Insufficiency, Chronic — 14 open to participants now, 16 under way, 4 of them phase 3. finerenone · Renal Insufficiency, Chronic.

Enrollment
Largest of 25
5,734 · median 100
Started
2015
the only one that year
Phase 3
6 of 25
3 open now
Registered
1st of 25
by date
Lead sponsor
8 of 25
Bayer

Among the 25 studies testing finerenone in Renal Insufficiency, Chronic, this one has the largest enrollment, is the only one that started in 2015, is one of 6 in phase 3, and was the 1st registered.

Renal Insufficiency, Chronic

3,096 studies on the registry are indexed under Renal Insufficiency, Chronic; 701 are open to participants now.

Browse Renal Insufficiency, Chronic studies →

Open to participants now

14 of the 25 studies testing finerenone in Renal Insufficiency, Chronic are open now, in 12 countries. Recruiting first, the newest first:

9 more — sign in →

By country, each count listing its studies:

All 14 open studies →

About finerenone

finerenone: first FDA approval 2021 (KERENDIA), first EMA approval 2022. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 435 Renal Insufficiency, Chronic studies recruiting now, 244 (56%) set no upper age limit and 111 (26%) stop at 75 or younger; 45 take children under 18; 80 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 25 studies testing finerenone in Renal Insufficiency, Chronic, or all of them as a file.
02

Study summary

The primary objective of this study was to demonstrate whether, in addition to standard of care, finerenone is superior to placebo in delaying the progression of kidney disease, as measured by the composite endpoint of time to first occurrence of kidney failure, a sustained decrease of estimated glomerular filtration rate (eGFR) ≥40% from baseline over at least 4 weeks, or renal death.

03

Conditions studied

  • Chronic Kidney Disease

Keywords

  • CKD
  • Diabetic Kidney Disease
  • Type 2 Diabetes
  • Kidney diseases
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Men or women ≥18 years of age
  • Type 2 diabetes mellitus (T2D) as defined by the American Diabetes Association
  • Diagnosis of chronic kidney disease (CKD) with at least one of the following criteria at run-in and screening visits:

    • persistent high albuminuria (UACR ≥30 to \<300 mg/g in 2 out of 3 first morning void samples) and estimated (eGFR) ≥25 but \<60 mL/min/1.73 m² (CKD EPI) and presence of diabetic retinopathy or
    • persistent very high albuminuria (UACR ≥300 mg/g in 2 out of 3 first morning void samples) and eGFR ≥25 to \<75 mL/min/1.73 m² (CKD-EPI)
  • Prior treatment with angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs) as follows:

    • For at least 4 weeks prior to the run-in visit, subjects should be treated with either an ACEI or ARB, or both
    • Starting with the run-in visit, subjects should be treated with only an ACEI or ARB
    • For at least 4 weeks prior to the screening visit, subjects should be treated with the maximum tolerated labeled dose (but not below the minimal labeled dose) of only an ACEI or an ARB (not both) preferably without any adjustments to dose or choice of agent or to any other antihypertensive or antiglycemic treatment
  • Serum potassium ≤4.8 mmol/L at both the run-in and the screening visit

Exclusion criteria

Exclusion Criteria:

  • Known significant non-diabetic renal disease, including renal artery stenosis
  • Uncontrolled arterial hypertension (ie, mean sitting systolic blood pressure (SBP) ≥170 mmHg, sitting diastolic blood pressure (DBP) ≥110 mmHg at run-in visit, or mean sitting SBP ≥160 mmHg, sitting DBP ≥100 mmHg at screening)
  • (HbA1c) >12%
  • Mean SBP \< 90 mmHg at the run-in visit or at the screening visit
  • Clinical diagnosis of chronic heart failure with reduced (HFrEF) and persistent symptoms ( [NYHA] class II - IV) at run-in visit (class 1A recommendation for mineralcorticoid receptor antagonists [MRAs])
  • Stroke, transient ischemic cerebral attack, acute coronary syndrome, or hospitalization for worsening heart failure, in the last 30 days prior to the screening visit
  • Dialysis for acute renal failure within 12 weeks of run-in visit
  • Renal allograft in place or scheduled within next 12 months from the run-in visit
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
5,734 participants (actual)

Study arms

  • Experimental
    Finerenone (BAY94-8862)

    Participants received finerenone 10 mg or 20 mg once daily in addition to standard of care therapy

    Drug: Finerenone (BAY94-8862)

  • Placebo comparator
    Placebo

    Participants received matching placebo once daily in addition to standard of care therapy

    Drug: Placebo

Interventions

  • Oral tablet; starting dose at 10 mg for subjects with an eGFR between 25 to \< 60 mL/min/1.73m² at the Screening Visit; starting dose at 20 mg for subjects with an eGFR ≥ 60 mL/min/1.73m² at the Screening Visit; dose could be up-titrated from Month 1 onwards or down-titrated at any time during the study; once daily in the morning, until the trial was completed provided there were no safety grounds for discontinuing treatment

  • DrugPlacebo

    Matching placebo, oral tablet, once daily in the morning, until the trial was completed provided there were no safety grounds for discontinuing treatment

06

What researchers measure

Primary outcomes

  1. The First Occurrence of the Composite Endpoint of Onset of Kidney Failure, a Sustained Decrease of eGFR ≥40% From Baseline Over at Least 4 Weeks, or Renal Death

    Count of participants and time from randomization to the first occurrence of the primary renal composite outcome, onset of kidney failure, a sustained decrease of eGFR ≥40% from baseline over at least 4 weeks, or renal death were evaluated. Number of participants with the outcome event is reported as descriptive result and hazard ratio is reported as statistical analysis.

    Time frame: From randomization up until the first occurrence of the primary renal composite endpoint, or censoring at the end of the study, with an average follow-up time of 32 months

Secondary outcomes

  1. The First Occurrence of the Composite Endpoint of Cardiovascular Death, Non-fatal Myocardial Infarction, Non-fatal Stroke, or Hospitalization for Heart Failure

    Count of participants and time from randomization to the first occurrence of the key secondary cardiovascular (CV) composite outcome, CV death, non-fatal myocardial infarction (MI), non-fatal stroke, or hospitalization for heart failure were evaluated. Number of participants with the outcome event is reported as descriptive result and hazard ratio is reported as statistical analysis.

    Time frame: From randomization up until the first occurrence of the key secondary CV composite endpoint, or censoring at the end of the study, with an average of 32 months

  2. All-cause Mortality

    Count of participants and time from randomization until death due to any cause were evaluated. Number of participants with outcome death is reported as descriptive result and hazard ratio is reported as statistical analysis. Number of participants with outcome death reported here includes deaths occurred after randomization until the end of the study visit. Deaths after end of study visit are not included in this table.

    Time frame: From randomization up until death due to any cause, or censoring at the end of the study visit, with an average of 32 months

  3. All-cause Hospitalization

    Count of participants and time from randomization to the first occurrence of a hospitalization event were evaluated. Number of participants with the event is reported as descriptive result and hazard ratio is reported as statistical analysis.

    Time frame: From randomization up until the first occurrence of the hospitalization due to any cause, or censoring at the end of study, with an average of 32 months

  4. Change in Urinary Albumin-to-creatinine Ratio (UACR) From Baseline to Month 4

    First morning void urine samples were collected to evaluate the urinary albumin-to-creatinine ratio (UACR). Month 4 was the visit closest to day 120 within a time window of 120 ± 30 days after randomization. If no measurements were available in this time window, the participant was excluded from this analysis. Ratio of UACR at Month 4 to UACR at baseline is reported as the change.

    Time frame: From baseline up until Month 4

  5. The First Occurrence of the Composite Endpoint of Onset of Kidney Failure, a Sustained Decrease in eGFR of ≥57% From Baseline Over at Least 4 Weeks, or Renal Death

    Count of participants and time from randomization to the first occurrence of the secondary renal composite outcome, onset of kidney failure, a sustained decrease in eGFR of ≥57% from baseline over at least 4 weeks, or renal death were evaluated. Number of participants with the outcome event is reported as descriptive result and hazard ratio is reported as statistical analysis.

    Time frame: From randomization up until the first occurrence of the composite primary endpoint, or censoring at the end of the study, with an average of 32 months

07

Results

Posted Jul 19, 2021

Participant flow

Study was conducted at multiple centers in 48 countries/regions between 17-SEP-2015 (first participant first visit) and 14-APR-2020 (last participant last visit).

Participant flow — Overall Study
MilestoneFinerenonePlacebo
Started28662868
Included in fas28332841
Treated28272831
Completed28242832
Not completed4236
Withdrew: Lost to follow-up53
Withdrew: Withdrawal by subject46
Withdrew: Gcp violations3327

Outcome measures

PrimaryThe First Occurrence of the Composite Endpoint of Onset of Kidney Failure, a Sustained Decrease of eGFR ≥40% From Baseline Over at Least 4 Weeks, or Renal Death

Count of participants and time from randomization to the first occurrence of the primary renal composite outcome, onset of kidney failure, a sustained decrease of eGFR ≥40% from baseline over at least 4 weeks, or renal death were evaluated. Number of participants with the outcome event is reported as descriptive result and hazard ratio is reported as statistical analysis.

Time frame:
From randomization up until the first occurrence of the primary renal composite endpoint, or censoring at the end of the study, with an average follow-up time of 32 months
Reported as:
Count of participants · Participants
The First Occurrence of the Composite Endpoint of Onset of Kidney Failure, a Sustained Decrease of eGFR ≥40% From Baseline Over at Least 4 Weeks, or Renal Death
ParticipantsFinerenonePlacebo
The First Occurrence of the Composite Endpoint of Onset of Kidney Failure, a Sustained Decrease of eGFR ≥40% From Baseline Over at Least 4 Weeks, or Renal Death504600
Statistical analysis
  • Finerenone vs Placebo · Log Rank · p = = 0.0014 (P-value from stratified log-rank test. Significance was considered to be achieved if p-value ≤ 0.03282695.) · Hazard ratio (hr): 0.825 · 95% CI 0.732 to 0.928A stratified Cox proportional hazards regression model was used to provide a point estimate of the hazard ratio and a corresponding two-sided 95% confidence interval.
SecondaryThe First Occurrence of the Composite Endpoint of Cardiovascular Death, Non-fatal Myocardial Infarction, Non-fatal Stroke, or Hospitalization for Heart Failure

Count of participants and time from randomization to the first occurrence of the key secondary cardiovascular (CV) composite outcome, CV death, non-fatal myocardial infarction (MI), non-fatal stroke, or hospitalization for heart failure were evaluated. Number of participants with the outcome event is reported as descriptive result and hazard ratio is reported as statistical analysis.

Time frame:
From randomization up until the first occurrence of the key secondary CV composite endpoint, or censoring at the end of the study, with an average of 32 months
Reported as:
Count of participants · Participants
The First Occurrence of the Composite Endpoint of Cardiovascular Death, Non-fatal Myocardial Infarction, Non-fatal Stroke, or Hospitalization for Heart Failure
ParticipantsFinerenonePlacebo
The First Occurrence of the Composite Endpoint of Cardiovascular Death, Non-fatal Myocardial Infarction, Non-fatal Stroke, or Hospitalization for Heart Failure367420
Statistical analysis
  • Finerenone vs Placebo · Log Rank · p = = 0.0339 (P-value from stratified log-rank test. Significance was considered to be achieved if p-value ≤ 0.04967388.) · Hazard ratio (hr): 0.860 · 95% CI 0.747 to 0.989A stratified Cox proportional hazards regression model was used to provide a point estimate of the hazard ratio and a corresponding two-sided 95% confidence interval.
SecondaryAll-cause Mortality

Count of participants and time from randomization until death due to any cause were evaluated. Number of participants with outcome death is reported as descriptive result and hazard ratio is reported as statistical analysis. Number of participants with outcome death reported here includes deaths occurred after randomization until the end of the study visit. Deaths after end of study visit are not included in this table.

Time frame:
From randomization up until death due to any cause, or censoring at the end of the study visit, with an average of 32 months
Reported as:
Count of participants · Participants
All-cause Mortality
ParticipantsFinerenonePlacebo
All-cause Mortality219244
Statistical analysis
  • Finerenone vs Placebo · Log Rank · p = = 0.2348 (P-value from stratified log-rank test. Significance was considered to be achieved if p-value ≤ 0.04967388.) · Hazard ratio (hr): 0.895 · 95% CI 0.746 to 1.075A stratified Cox proportional hazards regression model was used to provide a point estimate of the hazard ratio and a corresponding two-sided 95% confidence interval.
SecondaryAll-cause Hospitalization

Count of participants and time from randomization to the first occurrence of a hospitalization event were evaluated. Number of participants with the event is reported as descriptive result and hazard ratio is reported as statistical analysis.

Time frame:
From randomization up until the first occurrence of the hospitalization due to any cause, or censoring at the end of study, with an average of 32 months
Reported as:
Count of participants · Participants
All-cause Hospitalization
ParticipantsFinerenonePlacebo
All-cause Hospitalization12631321
Statistical analysis
  • Finerenone vs Placebo · Log Rank · p = = 0.1623 (P-value from stratified log-rank test.) · Hazard ratio (hr): 0.946 · 95% CI 0.876 to 1.022A stratified Cox proportional hazards regression model was used to provide a point estimate of the hazard ratio and a corresponding two-sided 95% confidence interval.
SecondaryChange in Urinary Albumin-to-creatinine Ratio (UACR) From Baseline to Month 4

First morning void urine samples were collected to evaluate the urinary albumin-to-creatinine ratio (UACR). Month 4 was the visit closest to day 120 within a time window of 120 ± 30 days after randomization. If no measurements were available in this time window, the participant was excluded from this analysis. Ratio of UACR at Month 4 to UACR at baseline is reported as the change.

Time frame:
From baseline up until Month 4
Reported as:
Least squares mean · Ratio
Change in Urinary Albumin-to-creatinine Ratio (UACR) From Baseline to Month 4
RatioFinerenonePlacebo
Change in Urinary Albumin-to-creatinine Ratio (UACR) From Baseline to Month 40.655 (0.637 to 0.673)0.952 (0.927 to 0.979)
Statistical analysis
  • Finerenone vs Placebo · ANCOVA · p = < 0.0001 (P-value from F-test of equal means between the treatment groups.) · Ratio of least squares means: 0.688 · 95% CI 0.662 to 0.715
SecondaryThe First Occurrence of the Composite Endpoint of Onset of Kidney Failure, a Sustained Decrease in eGFR of ≥57% From Baseline Over at Least 4 Weeks, or Renal Death

Count of participants and time from randomization to the first occurrence of the secondary renal composite outcome, onset of kidney failure, a sustained decrease in eGFR of ≥57% from baseline over at least 4 weeks, or renal death were evaluated. Number of participants with the outcome event is reported as descriptive result and hazard ratio is reported as statistical analysis.

Time frame:
From randomization up until the first occurrence of the composite primary endpoint, or censoring at the end of the study, with an average of 32 months
Reported as:
Count of participants · Participants
The First Occurrence of the Composite Endpoint of Onset of Kidney Failure, a Sustained Decrease in eGFR of ≥57% From Baseline Over at Least 4 Weeks, or Renal Death
ParticipantsFinerenonePlacebo
The First Occurrence of the Composite Endpoint of Onset of Kidney Failure, a Sustained Decrease in eGFR of ≥57% From Baseline Over at Least 4 Weeks, or Renal Death252326
Statistical analysis
  • Finerenone vs Placebo · Log Rank · p = = 0.0012 (P-value from stratified log-rank test.) · Hazard ratio (hr): 0.763 · 95% CI 0.648 to 0.900A stratified Cox proportional hazards regression model was used to provide a point estimate of the hazard ratio and a corresponding two-sided 95% confidence interval.

Adverse events

Collected over After the first dose of study drug up to 3 days after any temporary or permanent interruption of study drug, with an average treatment duration of 27 months. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Finerenone222/2,833 (7.8%)902/2,827 (31.9%)1,602/2,827 (56.7%)
Placebo250/2,841 (8.8%)971/2,831 (34.3%)1,584/2,831 (56%)
Most frequent serious events
Showing 10 of 952
Most frequent serious events
EventFinerenonePlacebo
PneumoniaInfections and infestations70/2827103/2831
Acute kidney injuryRenal and urinary disorders56/282751/2831
HyperkalaemiaMetabolism and nutrition disorders42/282712/2831
HypoglycaemiaMetabolism and nutrition disorders21/282731/2831
CellulitisInfections and infestations26/282722/2831
Urinary tract infectionInfections and infestations21/282723/2831
HyperglycaemiaMetabolism and nutrition disorders17/282723/2831
HypertensionVascular disorders15/282723/2831
Type 2 diabetes mellitusMetabolism and nutrition disorders14/282722/2831
SyncopeNervous system disorders12/282722/2831
Most frequent other events
Showing 10 of 15
Most frequent other events
EventFinerenonePlacebo
HyperkalaemiaMetabolism and nutrition disorders422/2827212/2831
Oedema peripheralGeneral disorders183/2827303/2831
HypertensionVascular disorders200/2827262/2831
NasopharyngitisInfections and infestations241/2827250/2831
AnaemiaBlood and lymphatic system disorders201/2827177/2831
DiarrhoeaGastrointestinal disorders183/2827188/2831
Upper respiratory tract infectionInfections and infestations181/2827185/2831
Urinary tract infectionInfections and infestations168/2827185/2831
Glomerular filtration rate decreasedInvestigations177/2827130/2831
Back painMusculoskeletal and connective tissue disorders175/2827170/2831

Baseline characteristics

Full analysis set (FAS): the FAS comprised all randomized participants (except those with critical GCP violations)

Age, Continuous
Age, Continuous(Years)FinerenonePlaceboTotal
Mean65.44 ± 8.9465.67 ± 9.1665.56 ± 9.05
Sex: Female, Male
Sex: Female, Male(Participants)FinerenonePlaceboTotal
Female8808111691
Male195320303983
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)FinerenonePlaceboTotal
Hispanic or Latino447431878
Not Hispanic or Latino237623974773
Unknown or Not Reported101323
Race (NIH/OMB)
Race (NIH/OMB)(Participants)FinerenonePlaceboTotal
American Indian or Alaska Native7876154
Asian7177231440
Native Hawaiian or Other Pacific Islander11718
Black or African American140124264
White177718153592
More than one race10186187
Unknown or Not Reported91019
Urinary albumin-to-creatinine ratio (UACR)
Urinary albumin-to-creatinine ratio (UACR)(milligram/gram (mg/g))FinerenonePlaceboTotal
Median832.72 (441.00 to 1628.14)867.01 (453.11 to 1644.58)851.87 (446.24 to 1634.22)
Estimated glomerular filtration rate (eGFR)
Estimated glomerular filtration rate (eGFR)(mL/min/1.73m^2)FinerenonePlaceboTotal
Mean44.36 ± 12.5444.32 ± 12.5744.34 ± 12.56
08

Study locations

978 sites
  • Birmingham, Alabama 35294, United States
  • Fort Payne, Alabama 35967, United States
  • Huntsville, Alabama 35801-4317, United States
  • Mesa, Arizona 85210, United States
  • Phoenix, Arizona 85016, United States
  • Phoenix, Arizona 85032, United States
  • Prescott, Arizona 86301, United States
  • Tucson, Arizona 85723, United States
  • Tucson, Arizona 85724, United States
  • Arvin, California 93203, United States
  • Chula Vista, California 91910, United States
  • Dublin, California 94568, United States
  • El Centro, California 92243, United States
  • Fresno, California 93720, United States
  • Fresno, California 93721, United States
  • La Mesa, California 91942, United States
  • Loma Linda, California 92357, United States
  • Los Angeles, California 90017, United States
  • Los Angeles, California 90022, United States
  • Los Angeles, California 90025, United States
  • Los Angeles, California 90073, United States
  • Northridge, California 91325, United States
  • Port Hueneme, California 93041, United States
  • Poway, California 92064, United States
  • Rancho Cucamonga, California 91730, United States
  • Rialto, California 92377, United States
  • Roseville, California 95661, United States
  • San Diego, California 92117, United States
  • San Francisco, California 94110, United States
  • Torrance, California 90502, United States
  • New Haven, Connecticut 06520, United States
  • Waterbury, Connecticut 06708, United States
  • Fleming Island, Florida 32003, United States
  • Fort Lauderdale, Florida 33316-1958, United States
  • Gainesville, Florida 32610-0224, United States
  • Hialeah, Florida 33012, United States
  • Hialeah, Florida 33016, United States
  • Hollywood, Florida 33024, United States
  • Jacksonville, Florida 32204, United States
  • Miami Beach, Florida 33140, United States
  • Miami Gardens, Florida 33169, United States
  • Miami Lakes, Florida 33014, United States
  • Miami Lakes, Florida 33016, United States
  • Miami, Florida 33032, United States
  • Miami, Florida 33126, United States
  • Miami, Florida 33130, United States
  • Miami, Florida 33144, United States
  • Miami, Florida 33145, United States
  • Miami, Florida 33155, United States
  • Miami, Florida 33156, United States
  • Miami, Florida 33165, United States
  • Miami, Florida 33173, United States
  • Miami, Florida 33175, United States
  • Miami, Florida 33180, United States
  • Miami, Florida 33186, United States
  • New Port Richey, Florida 34652, United States
  • Ocala, Florida 34471, United States
  • Orlando, Florida 32825, United States
  • Palm Harbor, Florida 34684, United States
  • Sarasota, Florida 34239, United States
  • Tampa, Florida 33614, United States
  • Tampa, Florida 33619, United States
  • Winter Haven, Florida 33880, United States
  • Atlanta, Georgia 30303, United States
  • Atlanta, Georgia 30318, United States
  • Atlanta, Georgia 30342, United States
  • Augusta, Georgia 30904, United States
  • Duluth, Georgia 30096, United States
  • Lilburn, Georgia 30047, United States
  • Macon, Georgia 31210, United States
  • Honolulu, Hawaii 96814, United States
  • Chicago, Illinois 60611, United States
  • Chicago, Illinois 60612, United States
  • Elgin, Illinois 60123, United States
  • Indianapolis, Indiana 46202, United States
  • Iowa City, Iowa 52242, United States
  • Hutchinson, Kansas 67502-1131, United States
  • Topeka, Kansas 66606, United States
  • Wichita, Kansas 67214, United States
  • Metairie, Louisiana 70006, United States
  • Monroe, Louisiana 71201, United States
  • New Orleans, Louisiana 70112, United States
  • Shreveport, Louisiana 71101, United States
  • Takoma Park, Maryland 20912, United States
  • Boston, Massachusetts 02215, United States
  • Ann Arbor, Michigan 48109, United States
  • Flint, Michigan 48504, United States
  • Flint, Michigan 48532, United States
  • Minneapolis, Minnesota 55455, United States
  • Columbia, Missouri 65201, United States
  • Columbia, Missouri 65212, United States
  • Jefferson City, Missouri 65109, United States
  • Kansas City, Missouri 64111, United States
  • Kansas City, Missouri 64128, United States
  • Saint Louis, Missouri 63106, United States
  • Saint Louis, Missouri 63136, United States
  • Lincoln, Nebraska 68510, United States
  • Omaha, Nebraska 68124, United States
  • Omaha, Nebraska 68131, United States
  • Las Vegas, Nevada 89086, United States

Showing the first 100 of 978 sites across 48 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Bakris GL, Agarwal R, Anker SD, Pitt B, Ruilope LM, Nowack C, Kolkhof P, Ferreira AC, Schloemer P, Filippatos G; on behalf of the FIDELIO-DKD study investigators; FIDELIO-DKD study investigators. Design and Baseline Characteristics of the Finerenone in Reducing Kidney Failure and Disease Progression in Diabetic Kidney Disease Trial. Am J Nephrol. 2019;50(5):333-344. doi: 10.1159/000503713. Epub 2019 Oct 25. PubMed 31655812 ↗
  • Bakris GL, Agarwal R, Anker SD, Pitt B, Ruilope LM, Rossing P, Kolkhof P, Nowack C, Schloemer P, Joseph A, Filippatos G; FIDELIO-DKD Investigators. Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes. N Engl J Med. 2020 Dec 3;383(23):2219-2229. doi: 10.1056/NEJMoa2025845. Epub 2020 Oct 23. PubMed 33264825 ↗
  • Filippatos G, Anker SD, Agarwal R, Pitt B, Ruilope LM, Rossing P, Kolkhof P, Schloemer P, Tornus I, Joseph A, Bakris GL; FIDELIO-DKD Investigators. Finerenone and Cardiovascular Outcomes in Patients With Chronic Kidney Disease and Type 2 Diabetes. Circulation. 2021 Feb 9;143(6):540-552. doi: 10.1161/CIRCULATIONAHA.120.051898. Epub 2020 Nov 16. PubMed 33198491 ↗
  • Pitt B, Agarwal R, Anker SD, Ruilope LM, Rossing P, Ahlers C, Brinker M, Joseph A, Lambelet M, Lawatscheck R, Filippatos GS; FIDELIO-DKD and FIGARO-DKD Investigators. Association of Finerenone Use With Reduction in Treatment-Emergent Pneumonia and COVID-19 Adverse Events Among Patients With Type 2 Diabetes and Chronic Kidney Disease: A FIDELITY Pooled Secondary Analysis. JAMA Netw Open. 2022 Oct 3;5(10):e2236123. doi: 10.1001/jamanetworkopen.2022.36123. PubMed 36287567 ↗
  • Ruilope LM, Agarwal R, Anker SD, Filippatos G, Pitt B, Rossing P, Sarafidis P, Schmieder RE, Joseph A, Rethemeier N, Nowack C, Bakris GL; FIDELIO-DKD Investigators. Blood Pressure and Cardiorenal Outcomes With Finerenone in Chronic Kidney Disease in Type 2 Diabetes. Hypertension. 2022 Dec;79(12):2685-2695. doi: 10.1161/HYPERTENSIONAHA.122.19744. Epub 2022 Oct 12. PubMed 36252131 ↗
  • Rossing P, Burgess E, Agarwal R, Anker SD, Filippatos G, Pitt B, Ruilope LM, Gillard P, MacIsaac RJ, Wainstein J, Joseph A, Brinker M, Roessig L, Scott C, Bakris GL; FIDELIO-DKD Investigators. Finerenone in Patients With Chronic Kidney Disease and Type 2 Diabetes According to Baseline HbA1c and Insulin Use: An Analysis From the FIDELIO-DKD Study. Diabetes Care. 2022 Apr 1;45(4):888-897. doi: 10.2337/dc21-1944. Erratum In: Diabetes Care. 2023 Sep 1;46(9):1721. doi: 10.2337/dc23-er09. PubMed 35061867 ↗
  • Rossing P, Filippatos G, Agarwal R, Anker SD, Pitt B, Ruilope LM, Chan JCN, Kooy A, McCafferty K, Schernthaner G, Wanner C, Joseph A, Scheerer MF, Scott C, Bakris GL; FIDELIO-DKD Investigators. Finerenone in Predominantly Advanced CKD and Type 2 Diabetes With or Without Sodium-Glucose Cotransporter-2 Inhibitor Therapy. Kidney Int Rep. 2021 Oct 14;7(1):36-45. doi: 10.1016/j.ekir.2021.10.008. eCollection 2022 Jan. PubMed 35005312 ↗
  • Agarwal R, Anker SD, Filippatos G, Pitt B, Rossing P, Ruilope LM, Boletis J, Toto R, Umpierrez GE, Wanner C, Wada T, Scott C, Joseph A, Ogbaa I, Roberts L, Scheerer MF, Bakris GL. Effects of canagliflozin versus finerenone on cardiorenal outcomes: exploratory post hoc analyses from FIDELIO-DKD compared to reported CREDENCE results. Nephrol Dial Transplant. 2022 Jun 23;37(7):1261-1269. doi: 10.1093/ndt/gfab336. PubMed 34850173 ↗
  • Filippatos G, Bakris GL, Pitt B, Agarwal R, Rossing P, Ruilope LM, Butler J, Lam CSP, Kolkhof P, Roberts L, Tasto C, Joseph A, Anker SD; FIDELIO-DKD Investigators. Finerenone Reduces New-Onset Atrial Fibrillation in Patients With Chronic Kidney Disease and Type 2 Diabetes. J Am Coll Cardiol. 2021 Jul 13;78(2):142-152. doi: 10.1016/j.jacc.2021.04.079. Epub 2021 May 17. PubMed 34015478 ↗
  • Erraez S, Lopez-Mesa M, Gomez-Fernandez P. Mineralcorticoid receptor blockers in chronic kidney disease. Nefrologia (Engl Ed). 2021 May-Jun;41(3):258-275. doi: 10.1016/j.nefro.2020.10.001. Epub 2020 Dec 24. English, Spanish. PubMed 33358451 ↗
  • Agarwal R, Anker SD, Bakris G, Filippatos G, Pitt B, Rossing P, Ruilope L, Gebel M, Kolkhof P, Nowack C, Joseph A; FIDELIO-DKD and FIGARO-DKD Investigators. Investigating new treatment opportunities for patients with chronic kidney disease in type 2 diabetes: the role of finerenone. Nephrol Dial Transplant. 2022 May 25;37(6):1014-1023. doi: 10.1093/ndt/gfaa294. PubMed 33280027 ↗
  • Chung EY, Ruospo M, Natale P, Bolignano D, Navaneethan SD, Palmer SC, Strippoli GF. Aldosterone antagonists in addition to renin angiotensin system antagonists for preventing the progression of chronic kidney disease. Cochrane Database Syst Rev. 2020 Oct 27;10(10):CD007004. doi: 10.1002/14651858.CD007004.pub4. PubMed 33107592 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2015 to primary completion in Apr 2020, 54 months.

Results were first posted in Jul 2021, 1 year 3 months after primary completion.

Of 104 industry-sponsored phase 3 interventional studies under Renal Insufficiency, Chronic, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 49. This study's 54 months is above that.

Counting every sponsor, half of 145 studies reached it within 32 months; a quarter within 19 and three quarters within 54.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 2, 2015
First posted
Sep 4, 2015
StartActual
Sep 17, 2015
Primary completionActual
Apr 14, 2020
CompletionActual
Apr 14, 2020
Results first posted
Jul 19, 2021
Last update
Jul 24, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 24, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02540993
Lead sponsor
Bayer
Responsible party
Sponsor
First posted
Sep 4, 2015
Start date
Sep 17, 2015
Primary completion
Apr 14, 2020
Completion
Apr 14, 2020
Results posted
Jul 19, 2021
Last update
Jul 24, 2023

Study contacts

Bayer Study Director
study director · Bayer

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Finerenone

Start the discussion